Asia Pacific Glioma Treatment Market Forecast to 2030

Asia Pacific Glioma Treatment Market Forecast to 2030

Asia Pacific Glioma Treatment Market Forecast to 2030 – Regional Analysis – by Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), and End User (Hospital & Clinics and Ambulatory Surgical Center)

Send Enquiry
Item ID: BMIRE00029266 Category: Tag:

$2,485 – $3,885

Description

The Asia Pacific glioma treatment market is expected to grow from US$ 754.97 million in 2022 to US$ 1,538.88 million by 2030. It is estimated to grow at a CAGR of 9.3% from 2022 to 2030.

Increasing Opportunities in Emerging Economies Fuels Asia Pacific Glioma Treatment Market

Brazil, Russia, India, China, and South Africa (BRICS) are among the fastest-growing economies in the world. The healthcare sectors in these countries, as well as other developing economies, are projected to expand rapidly in the coming years. The expected growth is ascribed to changes in customer demand, an increase in awareness about healthcare services, and a continuous rise in the aging population. The global brain cancer diagnostics market is likely to grow significantly in the coming years with the proliferation of the healthcare sector. Further, increased government spending on healthcare facilities and consumer purchasing power contribute to the growth of the healthcare sector in developing countries.

Asian countries are witnessing continuous growth in their scientific capabilities, owing to the ongoing clinical research studies, centralized healthcare institutions, well-qualified and highly motivated workforces, and excellent clinical trial facilities. Further, many countries in Asia Pacific have a large and diverse patient pool, with ~60% of the global population residing in the region. Treatment guidelines prepared by regulatory bodies in the US and EU are followed in Asia Pacific for treating diseases, which offers solid prospects for significant and rapid patient recruitment. Thus, the growing healthcare sector in developing countries in Asia Pacific creates better opportunities for the Asia Pacific glioma treatment market players to expand their business.

Asia Pacific Glioma Treatment Market Overview

The Asia Pacific glioma treatment market in Asia Pacific is expected to grow at the fastest CAGR during the forecast period; China, India, and Japan are three major contributors to the market growth in this region. The market is mainly driven by increasing investments by the government and private sectors of the respective countries. A rise in collaborations among Asian countries and Western countries for the development of treatment, increasing demand for brain cancer treatments, and rising prevalence of brain tumors are a few of the key factors that are likely to drive the Asia Pacific glioma treatment market in this region during the forecast period.

China is a country with a vast population and has flourished healthcare infrastructure. The extent of social and economic development differs between the coastal area and rural areas. In the coastal regions, healthcare resources are relatively well developed and readily available compared to the rural areas in the west. Like any other developed and developing country, Japan also focuses on strengthening its healthcare system and providing better access to health systems to its citizens. The government is encouraging advancements in genomic testing through various programs and institutes. Moreover, the increasing geriatric population and the surging prevalence of brain tumors are expected to contribute to the development of the Asia Pacific glioma treatment market.

Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Million)

Asia Pacific Glioma Treatment Market Segmentation

The Asia Pacific glioma treatment market is segmented into disease, treatment type, grade, end user, and country.

Based on disease, the Asia Pacific glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held the largest share of the Asia Pacific glioma treatment market in 2022.

Based on treatment type, the Asia Pacific glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held the largest share of the Asia Pacific glioma treatment market in 2022.

Based on grade, the Asia Pacific glioma treatment market is segmented into low grade and high grade. The high grade segment held a larger share of the Asia Pacific glioma treatment market in 2022.

Based on end user, the Asia Pacific glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held a larger share of the Asia Pacific glioma treatment market in 2022.

Based on country, the Asia Pacific glioma treatment market is segmented into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. China dominated the Asia Pacific glioma treatment market in 2022.

Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd are some of the leading companies operating in the Asia Pacific glioma treatment market.

Summary Info

Industry:

Pricing options:

, ,

Geographical coverage:

, ,

Year of Publication:

At 9.3% CAGR, the Asia Pacific Glioma Treatment Market is speculated to be worth US$ 1,538.88 million by 2030, says the research team

According to the research team’ research, the Asia Pacific glioma treatment market was valued at US$ 754.97 million in 2022 and is expected to reach US$ 1,538.88 million by 2030, registering a CAGR of 9.3% from 2022 to 2030. Increase in prevalence of high-grade glioma and increasing opportunities in emerging economies are among the critical factors attributed to the Asia Pacific glioma treatment market expansion.

High-grade gliomas include aggressive brain tumors such as glioblastomas, anaplastic astrocytomas, and oligodendrogliomas. These tumors are characterized by their rapid growth, infiltrative behavior, and resistance to conventional treatment methods. High-grade gliomas are multifaceted tumors that are not yet fully understood, which is a major reason for their increasing incidence. Moreover, aging populations, environmental exposure, genetic predispositions, and improved diagnostic capabilities are other notable factors that result in a large number of cases. Gliomas, particularly glioblastomas, are known for their devastating impact on patients’ lives due to their location within the brain and ability to disrupt critical neurological functions.

The most frequent and dangerous type of brain tumor is glioblastoma. Globally, more than 250,000 new cases of primary malignant brain tumors are detected each year, with gliomas accounting for 77% of these occurrences. It still remains a rare disease, accounting for over 50% of primary malignant brain tumors.

On the contrary, the high cost of diagnosis hampers the Asia Pacific glioma treatment market.

Based on disease, the Asia Pacific glioma treatment market is segmented into astrocytoma, oligoastrocytoma, and oligodendroglioma. The astrocytoma segment held 71.1% share of Asia Pacific glioma treatment market in 2022, amassing US$ 536.53 million. It is projected to garner US$ 1,123.67 million by 2030 to expand at 9.7% CAGR during 2022-2030.

Based on treatment type, the Asia Pacific glioma treatment market is segmented into surgery, chemotherapy, radiation therapy, and others. The surgery segment held 46.6% share of Asia Pacific glioma treatment market in 2022, amassing US$ 351.45 million. It is projected to garner US$ 751.39 million by 2030 to expand at 10.0% CAGR during 2022-2030.

Based on grade, the Asia Pacific glioma treatment market is segmented into low grade and high grade. The high grade segment held 80.7% share of Asia Pacific glioma treatment market in 2022, amassing US$ 609.53 million. It is projected to garner US$ 1,266.88 million by 2030 to expand at 9.6% CAGR during 2022-2030.

Based on end user, the Asia Pacific glioma treatment market is segmented into hospital & clinics and ambulatory surgical center. The hospital & clinics segment held 78.3% share of Asia Pacific glioma treatment market in 2022, amassing US$ 590.94 million. It is projected to garner US$ 1,213.87 million by 2030 to expand at 9.4% CAGR during 2022-2030.

Based on country, the Asia Pacific glioma treatment market has been categorized into China, Japan, India, South Korea, Australia, and the Rest of Asia Pacific. Our regional analysis states that China captured 31.0% share of Asia Pacific glioma treatment market in 2022. It was assessed at US$ 234.24 million in 2022 and is likely to hit US$ 495.74 million by 2030, exhibiting a CAGR of 9.8% during 2022-2030.

Key players operating in the Asia Pacific glioma treatment market are Amgen Inc, Amneal Pharmaceuticals Inc, Biocon Ltd, F. Hoffmann-La Roche Ltd, Merck & Co Inc, Pfizer Inc, Sun Pharmaceutical Industries Ltd, and Teva Pharmaceutical Industries Ltd, among others.

o Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Asia Pacific Glioma Treatment market.
o Highlights key in order to assist companies to realign their business strategies.
o The key findings and recommendations highlight crucial progressive industry trends in the Asia Pacific Glioma Treatment market, thereby allowing players across the value chain to develop effective long-term strategies.
o Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
o Scrutinize in-depth Asia Pacific market trends and outlook coupled with the factors driving the market, as well as those hindering it.
o Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.

TABLE OF CONTENTS

1. Introduction
1.1 The Research Team Report Guidance
1.2 Market Segmentation
2. Executive Summary
2.1 Key Insights
3. Research Methodology
3.1 Coverage
3.2 Secondary Research
3.3 Primary Research
4. Asia Pacific Glioma Treatment Market – Key Industry Dynamics
4.1 Market Drivers
4.1.1 Government Funding for Glioma Treatment
4.1.2 Increase in Prevalence of High-Grade Glioma
4.2 Key Market Restraints
4.2.1 High Cost of Diagnosis
4.3 Key Market Opportunities
4.3.1 Advancements in Healthcare Sector in Emerging Economies
4.4 Future Trends
4.4.1 Surge in Drug Approvals for Glioma Treatment
4.5 Impact Analysis:
5. Glioma Treatment Market – Asia Pacific Market Analysis
5.1 Asia Pacific Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
6. Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 – by Disease
6.1 Overview
6.2 Asia Pacific Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
6.3 Astrocytoma
6.3.1 Overview
6.3.2 Astrocytoma: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
6.4 Oligoastrocytoma
6.4.1 Overview
6.4.2 Oligoastrocytoma: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
6.5 Oligodendroglioma
6.5.1 Overview
6.5.2 Oligodendroglioma: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7. Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 – by Treatment Type
7.1 Overview
7.2 Asia Pacific Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
7.3 Surgery
7.3.1 Overview
7.3.2 Surgery: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.4 Chemotherapy
7.4.1 Overview
7.4.2 Chemotherapy: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.5 Radiation Therapy
7.5.1 Overview
7.5.2 Radiation Therapy: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
7.6 Others
7.6.1 Overview
7.6.2 Others: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8. Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 – by Grade
8.1 Overview
8.2 Asia Pacific Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
8.3 Low Grade
8.3.1 Overview
8.3.2 Low Grade: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.1 Grade I: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.3.2.2 Grade II: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4 High Grade
8.4.1 Overview
8.4.2 High Grade: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.1 Grade III: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
8.4.2.2 Grade IV: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9. Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 – by End User
9.1 Overview
9.2 Asia Pacific Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
9.3 Hospital & Clinics
9.3.1 Overview
9.3.2 Hospital & Clinics: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
9.4 Ambulatory Surgical Centers
9.4.1 Overview
9.4.2 Ambulatory Surgical Centers: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
10. Asia Pacific Glioma Treatment Market – Country Analysis
10.1 Overview
10.1.1 Asia Pacific Glioma Treatment Market, by Country
10.1.1.1 China
10.1.1.1.1 China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.1.2 China: Asia Pacific Glioma Treatment Market, by Disease
10.1.1.1.3 China: Asia Pacific Glioma Treatment Market, by Treatment Type
10.1.1.1.4 China: Asia Pacific Glioma Treatment Market, by Grade
10.1.1.1.4.1 China: Asia Pacific Glioma Treatment Market, by Low Grade
10.1.1.1.4.2 China: Asia Pacific Glioma Treatment Market, by High Grade
10.1.1.1.5 China: Asia Pacific Glioma Treatment Market, by End User
10.1.1.2 Japan
10.1.1.2.1 Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.2.2 Japan: Asia Pacific Glioma Treatment Market, by Disease
10.1.1.2.3 Japan: Asia Pacific Glioma Treatment Market, by Treatment Type
10.1.1.2.4 Japan: Asia Pacific Glioma Treatment Market, by Grade
10.1.1.2.4.1 Japan: Asia Pacific Glioma Treatment Market, by Low Grade
10.1.1.2.4.2 Japan: Asia Pacific Glioma Treatment Market, by High Grade
10.1.1.2.5 Japan: Asia Pacific Glioma Treatment Market, by End User
10.1.1.3 India
10.1.1.3.1 India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.3.2 India: Asia Pacific Glioma Treatment Market, by Disease
10.1.1.3.3 India: Asia Pacific Glioma Treatment Market, by Treatment Type
10.1.1.3.4 India: Asia Pacific Glioma Treatment Market, by Grade
10.1.1.3.4.1 India: Asia Pacific Glioma Treatment Market, by Low Grade
10.1.1.3.4.2 India: Asia Pacific Glioma Treatment Market, by High Grade
10.1.1.3.5 India: Asia Pacific Glioma Treatment Market, by End User
10.1.1.4 South Korea
10.1.1.4.1 South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.4.2 South Korea: Asia Pacific Glioma Treatment Market, by Disease
10.1.1.4.3 South Korea: Asia Pacific Glioma Treatment Market, by Treatment Type
10.1.1.4.4 South Korea: Asia Pacific Glioma Treatment Market, by Grade
10.1.1.4.4.1 South Korea: Asia Pacific Glioma Treatment Market, by Low Grade
10.1.1.4.4.2 South Korea: Asia Pacific Glioma Treatment Market, by High Grade
10.1.1.4.5 South Korea: Asia Pacific Glioma Treatment Market, by End User
10.1.1.5 Australia
10.1.1.5.1 Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.5.2 Australia: Asia Pacific Glioma Treatment Market, by Disease
10.1.1.5.3 Australia: Asia Pacific Glioma Treatment Market, by Treatment Type
10.1.1.5.4 Australia: Asia Pacific Glioma Treatment Market, by Grade
10.1.1.5.4.1 Australia: Asia Pacific Glioma Treatment Market, by Low Grade
10.1.1.5.4.2 Australia: Asia Pacific Glioma Treatment Market, by High Grade
10.1.1.5.5 Australia: Asia Pacific Glioma Treatment Market, by End User
10.1.1.6 Rest of Asia Pacific
10.1.1.6.1 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
10.1.1.6.2 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Disease
10.1.1.6.3 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Treatment Type
10.1.1.6.4 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Grade
10.1.1.6.4.1 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by Low Grade
10.1.1.6.4.2 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by High Grade
10.1.1.6.5 Rest of Asia Pacific: Asia Pacific Glioma Treatment Market, by End User
11. Asia Pacific Glioma Treatment Market Industry Landscape
11.1 Overview
11.2 Growth Strategies Done by the Companies in the Market, (%)
11.3 Organic Developments
11.3.1 Overview
11.4 Inorganic Developments
11.4.1 Overview
12. Company Profiles
12.1 F. Hoffmann-La Roche Ltd
12.1.1 Key Facts
12.1.2 Business Description
12.1.3 Products and Services
12.1.4 Financial Overview
12.1.5 SWOT Analysis
12.1.6 Key Developments
12.2 Merck & Co Inc
12.2.1 Key Facts
12.2.2 Business Description
12.2.3 Products and Services
12.2.4 Financial Overview
12.2.5 SWOT Analysis
12.2.6 Key Developments
12.3 Sun Pharmaceutical Industries Ltd
12.3.1 Key Facts
12.3.2 Business Description
12.3.3 Products and Services
12.3.4 Financial Overview
12.3.5 SWOT Analysis
12.3.6 Key Developments
12.4 Amgen Inc
12.4.1 Key Facts
12.4.2 Business Description
12.4.3 Products and Services
12.4.4 Financial Overview
12.4.5 SWOT Analysis
12.4.6 Key Developments
12.5 Teva Pharmaceutical Industries Ltd
12.5.1 Key Facts
12.5.2 Business Description
12.5.3 Products and Services
12.5.4 Financial Overview
12.5.5 SWOT Analysis
12.5.6 Key Developments
12.6 Pfizer Inc
12.6.1 Key Facts
12.6.2 Business Description
12.6.3 Products and Services
12.6.4 Financial Overview
12.6.5 SWOT Analysis
12.6.6 Key Developments
12.7 Amneal Pharmaceuticals Inc
12.7.1 Key Facts
12.7.2 Business Description
12.7.3 Products and Services
12.7.4 Financial Overview
12.7.5 SWOT Analysis
12.7.6 Key Developments
12.8 Biocon Ltd
12.8.1 Key Facts
12.8.2 Business Description
12.8.3 Products and Services
12.8.4 Financial Overview
12.8.5 SWOT Analysis
12.8.6 Key Developments
13. Appendix
13.1 About Us
13.2 Glossary of Terms

LIST OF TABLES

Table 1. Asia Pacific Glioma Treatment Market Segmentation
Table 2. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 3. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 4. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 5. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 6. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 7. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 8. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 9. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 10. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 11. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 12. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 13. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 14. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 15. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 16. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 17. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 18. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 19. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 20. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 21. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 22. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 23. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 24. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – High Grade
Table 25. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 26. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 27. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 28. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 29. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 30. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 31. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 32. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Disease
Table 33. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – Treatment Type
Table 34. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Grade
Table 35. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -Low Grade
Table 36. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) -High Grade
Table 37. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn) – End User
Table 38. Organic Developments Done By Companies
Table 39. Inorganic Developments Done By Companies
Table 40. Glossary of Terms, Asia Pacific glioma treatment market

LIST OF FIGURES

Figure 1. Asia Pacific Glioma Treatment Market Segmentation, By Country
Figure 2. Asia Pacific Glioma Treatment Market – Key Industry Dynamics
Figure 3. Impact Analysis of Drivers and Restraints
Figure 4. Asia Pacific Glioma Treatment Market Revenue (US$ Mn), 2022 – 2030
Figure 5. Asia Pacific Glioma Treatment Market Revenue Share, by Disease 2022 & 2030 (%)
Figure 6. Astrocytoma: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 7. Oligoastrocytoma: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 8. Oligodendroglioma: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 9. Asia Pacific Glioma Treatment Market Revenue Share, by Treatment Type 2022 & 2030 (%)
Figure 10. Surgery: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 11. Chemotherapy: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 12. Radiation Therapy: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 13. Others: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 14. Asia Pacific Glioma Treatment Market Revenue Share, by Grade 2022 & 2030 (%)
Figure 15. Low Grade: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 16. Grade I: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 17. Grade II: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 18. High Grade: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 19. Grade III: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 20. Grade IV: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 21. Asia Pacific Glioma Treatment Market Revenue Share, by End User 2022 & 2030 (%)
Figure 22. Hospital & Clinics: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 23. Ambulatory Surgical Centers: Asia Pacific Glioma Treatment Market – Revenue and Forecast to 2030 (US$ Million)
Figure 24. Asia Pacific Glioma Treatment Market, By Geography, 2022 ($Mn)
Figure 25. Asia Pacific Glioma Treatment Market, By Key Countries, 2022 And 2030 (%)
Figure 26. China: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 27. Japan: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 28. India: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 29. South Korea: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 30. Australia: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 31. Rest of Asia Pacific: Asia Pacific Glioma Treatment Market Revenue and Forecast to 2030 (US$ Mn)
Figure 32. Growth Strategies Done by the Companies in the Market, (%)

The List of Companies – Asia Pacific Glioma Treatment Market

1. Amgen Inc
2. Amneal Pharmaceuticals Inc
3. Biocon Ltd
4. F. Hoffmann-La Roche Ltd
5. Merck & Co Inc
6. Pfizer Inc
7. Sun Pharmaceutical Industries Ltd
8. Teva Pharmaceutical Industries Ltd

Reviews

There are no reviews yet.

Be the first to review “Asia Pacific Glioma Treatment Market Forecast to 2030”